Abstract

K. K. Igwe*, Q. N. Ebuzor, Chika Ikenga, N. K. Achi, A. J. Madubuike, I. E. Otuokere, I. I. Ijeh and P. E. Aba

ABSTRACT

Anti-diabetic effect of Andrographis paniculata leaves and serum biochemistry were studied in rats. Compounds in A. Paniculata were also analysed using GCMS and molecular docking study. Thirty (30) rats were used for the research and were grouped into six (6) of five (5) rats each. Group 1 was the normal control group and was administered distilled water. Groups 2 was diabetic non- treated. Groups 3, 4 and 5 were the treatment groups which received 500, 1000 and 1500 mg/kg body weight of the extract A. paniculata respectively. Group 6 was the positive Glibenclamide know drug. The rats were dosed for 14 days, thereafter were sacrificed by cardiac puncture and blood collected for analysis. All results in treatment groups were compared with the untreated diabetic group at statistical confidence of 95% (p<0.05). The normal control group saved as reference point. There was progressive recovery from diabetes induced rats as the blood glucose level reduced to normal range. Hb, PCV and RBC values were restored to normal. AST, ALT and ALP were within normal range indicating liver safety. Urea, creatinine and bilirubin were not affected showing kidney safety. Gas chromatogram showed 13 peaks indicating 13 phytocompounds present in A. Paniculata with OLA, HDA and MDH as the most abundant compounds. Molecular interaction and docking score of selected A. paniculata phytocompounds with α-amylase (1B2Y) complexes shows that 1B2Y-OLA, 1B2Y-HDA and 1B2Y-MHDcomplexes gave a docking score of -4.2 Kcal/mol, -4.5 Kcal/mol and -4.5 Kcal/mol respectively. The negative binding energy (exergonic) value suggests that the docking process was successful. Drug-likeness prediction showed 1 violation out of 5, for the compounds of A. paniculata. This suggests that all the docked compounds met the requirements of Lipinski Rule of 5 (RO5). These results suggest that A. paniculata compounds will be good candidates for drug development process.